Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC)
15 February 2022 – After multiple safety reviews, the use of hydroxyethyl-starch (HES) solutions for infusion was restricted to minimize the risk of kidney injury and death in certain patients. However, a recent study shows that HES solutions for infusion are still being used outside of the recommendations included in the product information. Therefore, EMA`s safety committee (PRAC) has recommended that marketing authorizations for HES solutions for infusion should be suspended across the EU.
For more information, see here.